Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study

Pediatrics

Volumn 121, Issue 5, 2008, Pages

  Freeman, Katherine ^a   Tan, Hooi Kuan ^b   Prusa, Andrea ^c   Petersen, Eskild ^d   Buffolano, Wilma ^e   Malm, Gunilla ^f   Cortina Borja, Mario ^b   Gilbert, Ruth ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Congenital toxoplasmosis; Prospective cohort; Retinochoroiditis; Treatment effectiveness

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PYRIMETHAMINE PLUS SULFONAMIDE; SPIRAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN DAMAGE; CATARACT; CHEMOPROPHYLAXIS; CHILD; CHORIORETINITIS; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; DISEASE MARKER; EUROPE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEPATOSPLENOMEGALY; HIGH RISK PATIENT; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MICROPHTHALMIA; NEUROLOGIC DISEASE; ONSET AGE; OPHTHALMOSCOPY; POSTNATAL CARE; PRENATAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; SEROCONVERSION; SURVIVAL; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; VITREOUS OPACITY; CLINICAL TRIAL; INFANT; MULTICENTER STUDY; NEWBORN; NEWBORN SCREENING; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DIAGNOSIS; RISK FACTOR; TOXOPLASMOSIS;

CHILD; CHILD, PRESCHOOL; CHORIORETINITIS; EUROPE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL DIAGNOSIS; PROGNOSIS; RISK FACTORS; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; TOXOPLASMOSIS, OCULAR;

EID: 44449144121     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2169     Document Type: Article

References (18)

1. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centers. Acta Paediatr. 2005;94(12):1-12
2. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004;113(6):1567-1572
3. Tan HK, Schmidt D, Stanford MR, et al. Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophthalmol. 2007;144(5):648-653
4. Gilbert R, Dezateux C. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child. 2006;91(8):629-631
5. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiebaut R, Leproust S, Chene G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007;369(9556):115-122
6. Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect. 2003;131(3): 1157-1168
7. Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet. 1999;353(9167):1834-1837
8. Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG. 2003;110(2):112-120
9. Thalib L, Gras L, Romand S, et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG. 2005;112(5):567-574
10. Therneau TM, Grambsch PM. Multiple Events Per Subject. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000:169-194
11. Thulliez P. Screening programme for congenital toxoplasmosis in France. Scand J Infect Dis. 1992;84(suppl):43-45
12. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol. 2001; 30(6):1309 -1330
13. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect. 2001;127(1):113-120
14. Gilbert RE, Harden M, Stanford MR. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2002;(1)
15. Daveluy A, Haramburu F, Bricout H, et al. Review of Data Related to Side Effects ofDrugs Used in Congenital Toxoplasmosis. Bordeaux, France: EUROTOXO A European Consensus on the State of the Science; 2005
16. Freeman K, Salt A, Prusa A, et al. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns and impairments, in 3 year old children. BMC Pediatr. 2005;5:23
17. Lehmann T, Marcet PL, Graham DH, Dahl ER, Dubey JP. Globalization and the population structure of Toxoplasma gondii. ProcNatlAcad Sci USA. 2006;103(30):11423-11428
18. Ajzenberg D, Banuls AL, Su C, et al. Genetic diversity, clonality and sexuality in Toxoplasma gondii. Int J Parasitol. 2004; 34(10):1185-1196